Rocklatan® Evaluation

Completed · Phase 4

Conditions studied: Glaucoma

In brief

The objective of this study is to evaluate the IOP-lowering effect when subjects are switched from various latanoprost-based regimens to Rocklatan. Subjects will stop their IOP-lowering medical therapy regimen and dose with Rocklatan for the duration of the study (12 weeks).

Key facts

Study ID
NCT05283395
Run by
Aerie Pharmaceuticals
People needed
136
Starts
2022-03-28
Expected to finish
2023-03-22
Last updated by the study team
2024-04-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.